Form 4: Opus Genetics Director, Jean Bennett, Acquires Shares and Options
SEC Form 4
Director Jean Bennett acquired shares and options in Opus Genetics, Inc. on April 30, 2025, through a grant of restricted stock units and stock options.
Summary
- On April 30, 2025, Jean Bennett, a director of Opus Genetics, Inc., acquired 79,504 shares of common stock and options to purchase 79,592 shares.
- The common stock was acquired through a grant of restricted stock units.
- These restricted stock units vest upon the earlier of one year from the grant date or the day before the next annual stockholder meeting, contingent on continued service.
- The stock options have an exercise price of $0.95 and expire on April 29, 2035.
- The options also vest upon the earlier of one year from the grant date or the day before the next annual stockholder meeting, contingent on continued service.
- Following these transactions, Bennett directly owns 213,525 shares of Opus Genetics, Inc.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. It reflects a routine transaction, but insider ownership is generally viewed favorably.
Positives
- A director's acquisition of shares and options can be seen as a positive signal, indicating confidence in the company's future prospects.
Future Outlook
The vesting of the restricted stock units and stock options is contingent upon the director's continued service, aligning their interests with the company's long-term success.
Industry Context
This filing is a routine disclosure related to insider transactions, common in the biotechnology industry where equity compensation is frequently used.
Comparison to Industry Standards
- Equity grants to directors are a common practice in the biotech industry to align their interests with shareholders.
- Companies like Regeneron and Vertex Pharmaceuticals also use stock options and restricted stock units as part of their director compensation packages.
- The vesting schedules and exercise prices are generally in line with industry norms for early-stage biotech companies.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment due to the director increasing their stake in the company.
Key Dates
| Date | Description |
|---|---|
| 04/30/2025 | Date of transaction: Grant of restricted stock units and stock options. |
| 04/30/2025 | Vesting start date: Restricted stock units and stock options vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. |
| 04/29/2035 | Expiration date of stock options. |
| 05/02/2025 | Date of Form 4 filing. |
Keywords
Opus Genetics, Director, Jean Bennett, Form 4, Stock Options, Restricted Stock Units, Beneficial Ownership, IRD
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.